Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Meda on Acquisition of Jazz Pharmaceuticals’ Women’s Health Products

September 6, 2012

LONDON, 06 September, 2012 — Covington & Burling LLP acted as legal advisers to Meda in an agreement with Jazz Pharmaceuticals to acquire a portfolio of six pharmaceutical products for women for $95 million in cash.

The largest and most important product in the portfolio is Elestrin, a patented product with sales of almost 100 MSEK, that doctors prescribe for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes associated with menopause.

Meda AB is a leading international specialty pharmaceutical company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries.

The Covington team was led by partners Peter Laveran and J. D. Weinberg with assistance from Karen Brooks. The team also included Rob Heller (tax), Michael Francese (benefits), Scott Cunningham, Stefanie Doebler and Jennifer Plitsch (regulatory), Paul Berman and Brianna Sandoval (intellectual property), and James Dean and David Addis (antitrust).

Share this article: